Story · FDA
Pfizer's prostate cancer drug combination gets U.S. FDA priority review
Pfizer announced on July 23, 2026, that the U.S. Food and Drug Administration (FDA) has granted priority review to its application seeking expanded approval for a combination of two prostate cancer drugs, Talzenna and Xtandi. The expanded approval is sought for men with metastatic castration-sensitive prostate cancer whose tumors have HRR mutations. Both drugs are already approved in the U.S. for men with prostate cancer that has spread and stopped responding to hormone therapy. The FDA has set a target decision date in the last quarter of 2026.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection